CHICAGO, Jan 31 (Reuters) - Medicis Pharmaceutical Corp (MRX.N: Quote, Profile, Research) said on Thursday the U.S. Food and Drug Administration had decided that the company’s Biologics License Application for the botulinum toxin type A, called Reloxin, in aesthetics was incomplete.
